A new ACC/AHA dyslipidemia guideline and editorial argue that guideline development is rigorous but can lag behind fast-moving science, using the VESALIUS-CV trial as a clear example. The trial showed that intensive LDL cholesterol lowering with evolocumab reduced cardiovascular events in high-risk patients without prior heart attack or stroke, with implications for future guideline updates.
from News Medical Medical Research News Feed https://ift.tt/f5whMPb
0 Comments